2018 Publications

  1. Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, et al. A Randomized, Placebo-Controlled Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection: The BORTEJECT Study. J Am Soc Nephrol 2018;29(2):591-605.
  2. Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C and Halloran PF. Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. J Am Soc Nephrol;28(6):1912-23.
  3. Famulski KS and Halloran PF. Letter to AJT editor re: Nankivell. Am J Transplant 2018;18(3):765-66.
  4. Halloran PF, Venner JM, Madill-Thomsen K, Einecke G, Parkes MD, Hidalgo LG, et al. Review: The transcripts associated with organ allograft rejection. Am J Transplant 2018;18(4)785-95.
  5. Eskandary F, Jilma B, Mulbacher J, Wahrmann M, Regele H, Kozakowski N, et al. Anti-C1s Monoclonal Antibody BIVV009 in Late Antibody-Mediated Kidney Allograft Rejection - Results from a First-in-Patient Phase 1 Trial. Am J Transplant 2018;18(4):916-26.
  6. Einecke G, Reeve J, Halloran PF. A molecular biopsy test based on arteriolar under-hyalinosis reflects increased probability of rejection related to under-immunosuppression. Am J Transplant 2018;18(4):821-31.
  7. Parkes MD, Halloran PF and Hidalgo LG. Mechanistic sharing between NK cells in ABMR and effector T cells in TCMR. Am J Transplant 2018;18(1):63-73.
  8. Halloran PF, Aliabadi AZ, Bruneval P, Cadeiras M, Crespo-Leiro MG, Deng M, et al. Exploring the cardiac response-to-injury in heart transplant biopsies. JCI Insight 2018;3(20):e123674.